Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Ozempic has been a hot topic in Hollywood with stars either admitting to using the diabetes drug for weight loss or staunchly ...

Kennedy has promised to "Make America Healthy Again" by tackling obesity with nutrition. Here's how he could rattle the ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

The drugs include Mounjaro, also known as tirzepatide, and semaglutide, which is sold under the brand names Wegovy, Ozempic ...

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according to a study ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits ...

Researchers at the University of Copenhagen have identified a new drug target for weight loss that curbs appetite, boosts ...